Month: April 2026

MENLO PARK, Calif., April 1, 2026 /PRNewswire/ — Global talent solutions and business consulting firm Robert Half (NYSE: RHI) has again been selected as one of Fortune’s 100 Best Companies to Work For^®. Robert Half’s consulting subsidiary, Protiviti, is also included on the highly competitive list.

Fortune 100 Best Companies to Work For recognizes top organizations with innovative programs that reflect a genuine commitment to meeting employee needs inside and outside the workplace, as validated by employee feedback. Great Place To Work^® analyzed anonymous survey responses from more than 1.3 million professionals from Great Place To Work Certified^™ companies with at least 1,000 employees in the U.S. Organizations are assessed on their efforts to create supportive, high-performance work experiences for every person in the organization.

“This recognition reflects our ongoing commitment to fostering a people-first approach,” said M. Keith Waddell, president and chief executive officer of Robert Half. “Our core values—integrity, inclusion, innovation and commitment to success—are embedded in our organizational culture, empowering employees to reach their full potential both personally and professionally.”

The survey also examined how responses varied across demographic groups and roles, providing insight into the consistency of the employee experience. Key indicators include accessibility to leaders, connection with colleagues and pride in work.

“Our focus remains on our people, with a commitment to supporting their growth and providing an environment where they can thrive and perform at their best,” said JoLynn Conway-James, senior executive director and chief administrative officer at Robert Half. “We take pride in our workplace culture, where employees feel valued, heard and supported.”

Robert Half is committed to supporting employees at every stage of their career and in the moments that matter most to them. In addition to ongoing recognition and mentoring programs, the company has invested in tools and technologies to improve the employee experience, including:

• Personalized learning paths: The organization customizes professional development and training by role and department, allowing employees to focus on the skills that support their growth and career advancement.
• Enhanced onboarding experience: By leveraging technology to simplify workflows, Robert Half offers an interactive and comprehensive onboarding experience for new employees and hiring managers, reducing manual effort and improving consistency across the organization.
• Self-service options: To help employees get faster answers to benefits questions, financial well-being needs (including retirement savings) and company policies, Robert Half offers a range of self-service tools, complemented by high-touch, individualized support.

FAQs
How does Robert Half support its employees?
Robert Half’s employee commitment focuses on supporting its people by prioritizing well-being, investing in career growth, fostering connection and empowering them to make a meaningful impact.

What innovative programs is Robert Half pursuing to build a world-class employee experience?
Through customized development opportunities and leadership pathways, a new performance review platform and continuous listening strategy, and emerging technologies that combine human judgment with AI-driven efficiency, employees are empowered to work smarter and stay future-ready.

Does Robert Half help clients build strong workplace cultures?
Robert Half helps clients build strong workplace cultures by delivering forward-looking talent solutions and consulting services aligned with their organizational goals.

About Robert Half
Robert Half is the world’s first and largest specialized talent solutions and business consulting firm, connecting highly skilled job seekers with rewarding opportunities at great companies. We offer contract talent and permanent placement solutions in the fields of finance and accounting, technology, marketing and creative, legal, and administrative and customer support, and we also provide executive search services. Robert Half is the parent company of Protiviti^®, a global consulting firm that delivers internal audit, risk, business and technology consulting solutions. In the past 12 months, Robert Half, including Protiviti, has been named one of the Fortune^® Most Admired Companies™ and one of Newsweek’s Most Charitable Companies. Explore talent solutions, research and insights at RobertHalf.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/robert-half-recognized-by-fortune-as-one-of-the-100-best-companies-to-work-for-302731529.html

SOURCE Robert Half

Adults taking Foundayo lost an average of 27 pounds on the highest dose in the ATTAIN-1 clinical trial¹

Foundayo, Lilly’s second FDA-approved obesity medicine, will be available via LillyDirect^® with free home delivery, starting at $25 per month with commercial coverage and $149 for self-pay

INDIANAPOLIS, April 1, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo will be available via LillyDirect^®, with prescriptions accepted immediately and shipping beginning April 6, followed shortly after by broad availability through U.S. retail pharmacies and telehealth providers.

“People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment,” said Deborah Horn, DO, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston. “With Foundayo, we now have an oral option that delivered an average of 12.4% weight loss at the highest dose in clinical trials – addressing both the clinical realities of obesity and the practical challenges patients face every day.”

Supported by the rigorous ATTAIN clinical trial program, Foundayo was proven to help people lose weight and keep it off. In the ATTAIN-1 trial, individuals taking the highest dose of Foundayo and who stayed on treatment lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with placebo.¹ Participants taking Foundayo, regardless of trial completion, lost an average of 25 pounds (11.1%), compared to 5.3 pounds (2.1%) with placebo.² In the ATTAIN program, Foundayo also led to reductions in many markers of cardiovascular risk, including waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure across all doses.

“Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn’t serious enough for treatment. We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications,” said David A. Ricks, chair and CEO of Eli Lilly and Company. “As a convenient, once-daily oral pill that delivers meaningful weight loss, this is obesity care designed for the real world.”

Lilly is committed to making Foundayo accessible and affordable. Eligible people with commercial insurance may pay as little as $25 per month with the Foundayo savings card.³ Individuals opting for self-pay can access Foundayo starting at $149 per month for the lowest dose. Additionally, eligible Medicare Part D individuals may be able to get Foundayo for $50 per month, beginning as soon as July 1, 2026.

Use of Foundayo with other GLP-1 receptor agonist medicines is not recommended. It is not known whether Foundayo is safe and effective for use in children. Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath. If you have any of these symptoms, tell your health care provider. The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Please see Indication and Safety Summary with Warning below and full Prescribing Information and Medication Guide.

“There is no single path that works for everyone living with overweight or obesity,” said Joe Nadglowski, president and CEO of the Obesity Action Coalition. “New treatment options expand choice and help more people find care that fits their lives, their goals and where they are in their journey – whether they’re just starting to explore treatment or looking for a different long-term approach.”

Lilly has submitted orforglipron for weight management and/or type 2 diabetes in more than 40 countries and plans to launch in each country shortly after approval.

For more information about Foundayo, please visit www.foundayo.lilly.com. 

About Foundayo (orforglipron)⁴
Foundayo™ (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake.⁵ Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.

About ATTAIN-1 and ATTAIN-2 clinical trial program
The ATTAIN Phase 3 global clinical development program for orforglipron has enrolled more than 4,500 people with obesity or overweight across two global registration trials.

ATTAIN-1 (NCT05869903) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes. The trial randomized 3,127 participants across the U.S., Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan to receive various doses of orforglipron or placebo along with healthy diet and physical activity. The primary objective of the study was to demonstrate that orforglipron is superior to placebo in body weight reduction from baseline after 72 weeks.

ATTAIN-2 (NCT05872620) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of various doses of orforglipron with placebo in adults with obesity or overweight and type 2 diabetes. The trial randomized over 1,600 participants across the U.S., Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, South Korea and Puerto Rico to receive various doses of orforglipron or placebo along with healthy diet and physical activity. The primary objective of the study was to demonstrate that orforglipron is superior to placebo in mean body weight change from baseline at 72 weeks.

INDICATION AND SAFETY SUMMARY WITH WARNINGS
Foundayo™ (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

• Foundayo should not be used with other GLP-1 receptor agonist medicines.
• It is not known if Foundayo is safe and effective for use in children.

Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

• Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
• Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo.

Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn’t go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking Foundayo

• Tell your healthcare provider about all the medicines you take. Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works.
• Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).
• If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo. Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo.
• Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.

Review these questions with your healthcare provider:

❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.
❑ Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.
❑ Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?

How to take

• Take Foundayo exactly as your healthcare provider tells you to.
• Use Foundayo with a reduced-calorie diet and increased physical activity.
• Take Foundayo by mouth 1 time each day, with or without food.
• Swallow tablets whole. Do not break, crush, or chew the tablet.
• If you miss a dose, take it as soon as possible. Do not take 2 doses of Foundayo in the same day.
• Do not take more than 1 tablet per day.
• If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment.
• If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Learn more
Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to foundayo.lilly.com.

This summary provides basic information about Foundayo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Foundayo and how to take it. Your doctor is the best person to help you decide if Foundayo is right for you.

OG CON BS APR2026

Foundayo^™ is a trademark of Eli Lilly and Company.

Endnotes and References 

1. The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and modifications) for 72 weeks without initiating prohibited weight management treatments.⁴
2. The treatment-regimen estimand represents the estimated average treatment effect regardless of adherence to study intervention or initiation of prohibited weight management treatments.⁴
3. Terms and conditions apply. Learn more at foundayo.lilly.com.
4. Foundayo. Prescribing Information. Lilly USA, LLC.
5. Ma X, Liu R, Pratt EJ, Benson CT, Bhattachar SN, Sloop KW. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024 Apr;15(4):819-832. https://doi.org/10.1007/s13300-024-01554-1. Epub 2024 Feb 24. PMID: 38402332; PMCID: PMC10951152.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. P-LLY

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Foundayo as a treatment for adults with obesity or some adults with overweight who also have weight-related medical problems and reflects Lilly’s current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with study results to date, that Foundayo will receive additional regulatory approvals, or that Foundayo will be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly’s expectations, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Trademarks and Trade Names 
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ^® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company’s or their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

CMAT-04552 04/2026 ©Lilly USA, LLC 2026. All rights reserved.

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html

SOURCE Eli Lilly and Company

Novel Transdermal Curcumin Formulation Demonstrates Pain Reduction and Improved Quality of Life in Phase 1b Clinical Trial

Study published in Frontiers in Pain Research reports significant reduction in knee pain with topical curcumin formulation

SUMMIT, N.J., April 1, 2026 /PRNewswire/ — Vascarta Inc. today announced the publication of results from a randomized, double-blind, placebo-controlled clinical trial evaluating VAS-101, the company’s investigational topical/transdermal curcumin gel, for the treatment of knee pain associated with osteoarthritis. The study appears in the peer-reviewed journal Frontiers in Pain Research. Frontiers | The effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study

The clinical trial demonstrated that participants using VAS-101 experienced statistically significant reductions in knee pain compared with placebo, along with a favorable safety and tolerability profile.

Dr. Adrian Lopresti, Managing Director of Clinical Trials Australia and principal investigator, stated, “The results of this study demonstrate that, in people with knee osteoarthritis, the topical application of VAS-101 reduced knee pain within 28 days, with clinically meaningful improvements occurring in approximately 40% of participants. VAS-101 may represent a promising option for individuals experiencing knee osteoarthritis.”

Study Design
The randomized, double-blind, placebo-controlled trial enrolled 60 adults aged 45–75 with knee osteoarthritis. Participants applied either 0.1 mL VAS-101 or 0.1 mL placebo gel to the affected knee every other day for 28 days.

Researchers assessed outcomes using several validated measures, including:

• KOOS pain subscale (primary endpoint)
• Daily pain ratings
• Performance-based physical function tests
• Use of rescue oral pain medication

Key Findings
Results from the study showed that VAS-101 produced meaningful improvements in pain outcomes compared with placebo:

• Significant improvement in KOOS pain score (β: 5.12; 95% CI: 0.47–9.77; p = 0.041)
• Significant reduction in daily pain ratings (p = 0.005)
• 39.3% of participants using VAS-101 reported feeling “much improved” or “very much improved,” compared with 13.3% in the placebo group (p = 0.019)
• 32.1% of participants achieved a Minimal Clinically Important Difference in symptoms, compared with 13.3% with placebo

VAS-101 was well tolerated, with no significant adverse reactions reported. Temporary skin staining, a known characteristic of topical curcumin, was observed but resolved within two to three days after discontinuation.

Implications
The study suggests that topical delivery of curcumin may offer a promising non-oral therapeutic approach to managing osteoarthritis-related knee pain, potentially addressing limitations associated with oral formulations.

While further research with larger patient populations and longer treatment durations is needed, these findings highlight the potential role of VAS-101 in managing osteoarthritis pain,” said Joel Friedman, M.D., Ph.D., inventor of Vascarta’s patented transdermal drug delivery technology, Professor Emeritus at Albert Einstein College of Medicine, and Chief Scientific Officer.

Chairman and CEO Richard Prince, Ph.D. added: “These data indicate the potential of VAS-101 to become the standard of care in osteoarthritis. We intend to accelerate our efforts in the development of VAS-101 for osteoarthritis with the anticipated filing of an Investigational New Drug Application to the United States Food & Drug Administration later this year.” 

About Knee Osteoarthritis
Knee osteoarthritis is a degenerative joint condition affecting millions of adults worldwide. It is characterized by chronic pain, stiffness, reduced mobility, and progressive deterioration of joint cartilage.

About VAS-101
VAS-101 is an investigational topical curcumin formulation developed and patented by Vascarta. It is designed to deliver curcumin through the skin directly into affected joints, potentially providing localized and enhanced systemic anti-inflammatory and analgesic effects.

About Vascarta
Vascarta Inc. is a clinical-stage pharmaceutical company focused on developing therapies to address chronic pain and inflammation. The company’s proprietary drug delivery platform supports a growing pipeline of therapies targeting inflammatory diseases and cancer.

The company’s lead candidate, Vasceptor® (VAS-101), is a topically applied transdermal formulation utilizing curcumin as its active pharmaceutical ingredient. By bypassing the gastrointestinal tract and first-pass liver metabolism, the transdermal route may enhance curcumin delivery into systemic circulation compared with oral formulations.

Contacts for further information:
Dr. Richard Prince
Chairman, CEO & President
rprince@vascarta.com

Mr. David Hymson
Communications
dhymson@vascarta.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vascarta-announces-positive-clinical-trial-results-for-topicaltransdermal-curcumin-gel-vas-101-in-knee-osteoarthritis-302731447.html

SOURCE Vascarta Inc

• Genesis Inspiration Foundation marks major milestone in long‑term commitment to creativity, access, and opportunity for young people nationwide

NEW YORK, April 1, 2026 /PRNewswire/ — Genesis Inspiration Foundation, a 501(c)(3) nonprofit organization committed to supporting education through the arts, announced it will award more than $3 million in 2026 to 91 youth arts organizations across the United States, a commitment that brings the Foundation’s total philanthropic giving to more than $16 million since 2018. Established to expand access to youth arts education, Genesis Inspiration Foundation represents a long‑term investment in creativity, helping ensure that young people, regardless of background, have opportunities to explore, learn, and express themselves through the arts.

“Over the past 10 years, Genesis has been building a brand built on design, performance, and purpose,” said Tedros Mengiste, chief operating officer of Genesis Motor North America. “Through Genesis Inspiration Foundation, we are making a sustained investment in arts education to help young people unlock their creativity, expand what they believe is possible, and build skills that will serve them for a lifetime.”

Genesis Inspiration Foundation provides support for youth arts programs nationwide, aiming to increase accessibility and foster creativity, especially within under-resourced communities. The arts play a critical role in fostering creativity, confidence, and critical thinking—skills essential to shaping future innovators and leaders.

“Genesis Inspiration Foundation exists to expand access to arts education and ensure young people have the opportunity to discover their creative potential,” said Walter Dawson, board chair, Genesis Inspiration Foundation. “Reaching more than $16 million in total giving reflects our commitment to creating opportunity, fostering creativity, and supporting the organizations that inspire the next generation.”

A portion of every new Genesis vehicle sold helps fund youth arts education through the Genesis Inspiration Foundation, with additional support provided by Genesis Motor America. Together, these contributions help thousands of children each day realize the full power of their imaginations while reinforcing Genesis’ commitment to contributing meaningfully to the communities it serves.

The complete list of grant recipients will be announced later this year.

Genesis Inspiration Foundation

Genesis Inspiration Foundation is a 501(c)(3) nonprofit organization committed to connecting youth to the transformative power of the arts. Our mission is to improve educational outcomes by providing access to arts programs that engage and inspire children in under-resourced communities. Founded in 2018, the Genesis Inspiration Foundation has awarded over $16 million in grants to expand youth arts at museums, schools, and community organizations nationwide. With the support of Genesis and its retailers, we are introducing children to a new world of possibilities. To learn more, visit us online at www.genesisinspirationfoundation.org.

Genesis Motor North America

Genesis is a new global automotive brand that delivers the highest standards of design, safety, refined performance, and innovation while looking towards a more sustainable future. Drawing from its cultural heritage and distinctly Korean hospitality, Genesis crafts experiences focused on customers as “son-nim”, or honored guests.

Genesis Motor North America offers a growing range of award-winning SUV, sedan, and electric models through its network of more than 200 independent U.S. retailers, in addition to its more than 30 Canadian agency distributors. Genesis now counts more than 100 standalone retail facilities across the North American region, with dozens more in development. Consumers can discover the brand through its many retail points, at Genesis House, the brand’s flagship space in New York City, or online at www.genesis.com.

Please visit our media site for the latest news at www.genesisnewsusa.com (United States) and www.genesisnews.ca (Canada).

View original content to download multimedia:https://www.prnewswire.com/news-releases/genesis-inspiration-foundation-celebrates-16-million-invested-in-youth-arts-education-302731205.html

SOURCE Genesis Motor America

• Genesis Inspiration Foundation marks major milestone in long‑term commitment to creativity, access, and opportunity for young people nationwide

NEW YORK, April 1, 2026 /PRNewswire/ — Genesis Inspiration Foundation, a 501(c)(3) nonprofit organization committed to supporting education through the arts, announced it will award more than $3 million in 2026 to 91 youth arts organizations across the United States, a commitment that brings the Foundation’s total philanthropic giving to more than $16 million since 2018. Established to expand access to youth arts education, Genesis Inspiration Foundation represents a long‑term investment in creativity, helping ensure that young people, regardless of background, have opportunities to explore, learn, and express themselves through the arts.

“Over the past 10 years, Genesis has been building a brand built on design, performance, and purpose,” said Tedros Mengiste, chief operating officer of Genesis Motor North America. “Through Genesis Inspiration Foundation, we are making a sustained investment in arts education to help young people unlock their creativity, expand what they believe is possible, and build skills that will serve them for a lifetime.”

Genesis Inspiration Foundation provides support for youth arts programs nationwide, aiming to increase accessibility and foster creativity, especially within under-resourced communities. The arts play a critical role in fostering creativity, confidence, and critical thinking—skills essential to shaping future innovators and leaders.

“Genesis Inspiration Foundation exists to expand access to arts education and ensure young people have the opportunity to discover their creative potential,” said Walter Dawson, board chair, Genesis Inspiration Foundation. “Reaching more than $16 million in total giving reflects our commitment to creating opportunity, fostering creativity, and supporting the organizations that inspire the next generation.”

A portion of every new Genesis vehicle sold helps fund youth arts education through the Genesis Inspiration Foundation, with additional support provided by Genesis Motor America. Together, these contributions help thousands of children each day realize the full power of their imaginations while reinforcing Genesis’ commitment to contributing meaningfully to the communities it serves.

The complete list of grant recipients will be announced later this year.

Genesis Inspiration Foundation

Genesis Inspiration Foundation is a 501(c)(3) nonprofit organization committed to connecting youth to the transformative power of the arts. Our mission is to improve educational outcomes by providing access to arts programs that engage and inspire children in under-resourced communities. Founded in 2018, the Genesis Inspiration Foundation has awarded over $16 million in grants to expand youth arts at museums, schools, and community organizations nationwide. With the support of Genesis and its retailers, we are introducing children to a new world of possibilities. To learn more, visit us online at www.genesisinspirationfoundation.org.

Genesis Motor North America

Genesis is a new global automotive brand that delivers the highest standards of design, safety, refined performance, and innovation while looking towards a more sustainable future. Drawing from its cultural heritage and distinctly Korean hospitality, Genesis crafts experiences focused on customers as “son-nim”, or honored guests.

Genesis Motor North America offers a growing range of award-winning SUV, sedan, and electric models through its network of more than 200 independent U.S. retailers, in addition to its more than 30 Canadian agency distributors. Genesis now counts more than 100 standalone retail facilities across the North American region, with dozens more in development. Consumers can discover the brand through its many retail points, at Genesis House, the brand’s flagship space in New York City, or online at www.genesis.com.

Please visit our media site for the latest news at www.genesisnewsusa.com (United States) and www.genesisnews.ca (Canada).

View original content to download multimedia:https://www.prnewswire.com/news-releases/genesis-inspiration-foundation-celebrates-16-million-invested-in-youth-arts-education-302731205.html

SOURCE Genesis Motor America

• A right-sized all-electric entry SUV, delivering EV9-inspired design, practical range, and everyday usability to make electric mobility affordable to a larger audience
• Kia’s E-GMP architecture enables 10-80 percent DC fast charging in as little as 29 minutes¹ on the Light trim
• Up to a Kia-estimated 320-miles of all-electric range (AER)² on certain trims
• Native NACS charging port w/ standard Plug and Charge (PnC) capability³ through Kia Charge Pass in the Kia Access app⁴
• Available all-wheel drive (AWD)⁵
• Innovative i-Pedal 3.0 technology⁶ and Smart Regeneration System⁷
• Available Vehicle to Load (V2L)⁸ capability turns EV3 into a useful power source for a variety of devices
• Standard eight airbags⁹ plus an impressive suite of Advanced Driver Assistance Systems (ADAS)¹⁰ including standard Forward Collision Avoidance (FCA) Assist¹¹
• Stand-out Opposites United design inspired by EV9
• High-performance GT model and special U.S.-exclusive available Nightfall black appearance package elevate EV3 in unique ways
• Unexpected segment-up features (as found on EV9) enhance the experience of this entry EV SUV with available: Head-up Display,¹² 360° Surround-View Monitor (SVM),¹³Blind-spot View Monitor, multicolor ambient mood lighting
• Key standard content: nearly 30-inches of total combined dash display¹⁴ (same as EV9) with Connected Car Navigation Cockpit (ccNC) with dual 12.3-inch displays¹⁴ and 5-inch climate display
• Available Entertainment and Data Services (EDS)¹⁵ enhances Kia’s existing music streaming and now includes video streaming through Netflix and YouTube¹⁶
• U.S. launch of Kia EV3 expected late 2026

NEW YORK, April 1, 2026 /PRNewswire/ — The all-new 2027 Kia EV3 made its North American debut today at the New York International Auto Show, setting a new benchmark as the most attainable model in Kia’s growing electric vehicle lineup, which includes the popular EV6 and EV9 models. The EV3 is an entry EV SUV that offers many of the advanced amenities of an EV9 in a smart and approachable package. Ultimately, it is designed to deliver efficient, all-electric performance with a compact footprint.

Experience the interactive Multimedia News Release here: https://www.multivu.com/kia/9375052-en-new-2027-kia-ev3-debuts-new-york-international-auto-show

“The Kia EV3 represents a bold step forward in our commitment to making electric mobility accessible to more Americans,” said Eric Watson, vice president, sales operations, Kia America. “With its striking geometric design inspired by EV9, advanced technology, and spacious interior, the EV3 brings the innovation of our EV lineup into an entry EV SUV tailored for the way U.S. customers live, work, and travel.”

The EV3 is tailored to meet the lifestyle and usage of both younger and older buyers, from millennials to baby boomers, centered on universally appealing attributes such as affordability, utility, and maneuverability.  Based on the 400V Electric Global Modular Platform (E-GMP), the EV3 features an energy-dense battery allowing up to a Kia-estimated² 320 miles of range on certain trims with fast charging capabilities.

Right-sized for those who welcome the invitation to go electric, the 2027 Kia EV3 will be available in five trim levels: Light, Wind, Land, GT-Line, and GT. It will go on sale in late 2026. Pricing will be announced closer to the EV3’s on-sale date.

Engaging on the Outside

Guided by Kia’s global Opposites United design philosophy, the EV3 juxtaposes contrasts found in nature with those of the human and industrial world. As such, it shares the same fundamental design language as Kia’s pioneering EV6 and EV9 models.

Upon approach, the first thing to catch the eye is the star map DRL design, Kia’s signature lighting concept with standard small cube LED projector head lamps. The vertically arranged lights emphasize the EV3’s broad front-end, while the horizontally configured lights underscore the latest interpretation of Kia’s Tiger Face, giving the EV3 an expressive and futuristic look. Overall, the EV3’s front-facing persona exudes EV9 like boldness and confidence in a concisely wrapped package.

The aerodynamic profile combines short overhangs and a sloping roof that gives the illusion that it’s floating as it moves rearward. Flush-type roof rails are standard (bridge-type roof rails are optional). The roofline leads back to the combination taillamps that reflect the Star Map lighting design found up front. The hidden rear door handles lend to the EV3’s clean side view similar to EV9.

The EV3’s planted stance meets the pavement with either standard 17-inch or available 19-inch alloy wheels wearing all-season tires. Compared to the base trims, the EV3 GT-Line and GT bring exclusive design elements to create more visually striking packages. The GT gets unique 19-inch wheels and eye-catching green brake caliper covers that match other exterior and interior neon green accents.

And on certain trims, a special Nightfall black appearance package, specifically imagined for the U.S., will be available. Nightfall will include unique gloss black wheels, black emblems, bridge-type roof rails, and a unique dark gray interior color to exude a more serious character.

Space, Comfort and Utility Inside

In the same way that ‘Opposites United’ defines the exterior of the EV3, Kia’s unique design language brings nature and humanity together on the inside. Here, designers applied durable materials while still achieving a rich look and feel.

The home-like cabin is headlined by an expansive standard panoramic display consisting of dual 12.3-inch displays and a 5-inch climate display. GT-Line includes a three-spoke steering wheel, metal pedals, and off-white 2-tone seats, while the GT model also gets sport bucket front seats and neon green accented seatbelts, steering wheel, and interior trim. 

The driver and front passenger area features a clean and open layout appealing to those who value simplicity and practicality. An open center console with retractable cupholders allows for flexible storage for larger items and features both open and covered storage compartments for the flexibility to meet customer needs.

The cabin experience is further elevated with standard dual-zone Fully Automatic Temperature Control (FATC), optional heated¹⁷ and ventilated front seats, and optional multicolor ambient mood lighting. Rear seat passengers can enjoy standard features such as seat backs that recline up to 39 degrees and air vents that provide a restful atmosphere.

In the cargo area, EV3 delivers on roominess and utility thanks to 60/40 flat folding rear seats, a generously sized cargo area with 56.5 cubic feet of capacity behind the first row and 26.1 cubic feet of capacity behind the second row, a standard two-position luggage board with underfloor storage, and a 0.9 cubic foot frunk, a feature not commonly found in this class. An optional Smart Power Liftgate is also available, which automatically opens by way of Smart Key for easy load-in of groceries or gear. Opening height and speed of the liftgate can be set through the infotainment system.

Electrified Power and Performance

Underpinned by Kia’s dedicated 400V E-GMP platform, the Kia EV3 is powered by a choice of two batteries options: a standard-range 58.3 kWh battery (Light) or a long-range 81.4 kWh battery (Wind, Land, GT-Line, GT). The smaller of the two batteries provides power to the front-wheels only, while the larger battery makes all-wheel-drive (AWD) possible (optional on Wind and Land; standard on GT-Line and GT). As far as all-electric range goes, the 58.3 kWh battery allows up to a Kia-estimated² 220 miles and the 81.4 kWh battery allows up to a Kia-estimated² 320 miles (FWD).

On the performance side, the EV3 GT outputs 288 horsepower (up from 261 hp on AWD EV3 models). Available Virtual Gear Shift (VGS) and Active Sound Design (ASD) further enhance driving engagement and help deliver a more spirited on-road experience.

The EV3’s driving stability, ride comfort and responsiveness are the result of a Macpherson strut suspension at the front and a multi-link geometry at the rear. The EV3 GT benefits from a sport-tuned suspension and steering. Aside from ride and handling prowess, advanced chassis development was aimed at reducing NVH.  Engineers added sound absorption throughout the body and applied damping materials to increase quietness for highway and around-town driving.

To further enhance efficiency and performance, the EV3’s aerodynamics have been improved. Kia expanded use of lightweight body materials, employed aero wheels, integrated a front bumper active air flap and installed a full underbody cover. The result is a drag coefficient of 0.275 Cd.

When it comes to DC fast charging, the EV3’s battery can power up from 10 to 80 percent charge in an estimated 29 minutes¹ for the 58.3 kWh (Light) battery and 31 minutes¹ for the 81.4 kWh (Wind, Land, GT-Line, GT) battery.

For ease of use, there’s a native NACS charging port on the front passenger side of the EV3. And with the standard Kia Plug and Charge (PnC)³ feature, the EV3 can now charge seamlessly by pulling up to a compatible charging station and plugging in. This process only requires a one-time login and setup through Kia Charge Pass in the Kia Access app.

Kia’s innovative i-Pedal 3.0⁶ system helps drivers to smoothly control the speed of the vehicle and can bring it to a complete stop using only the accelerator pedal. This feature works in tandem with EV3’s adaptive Smart Regeneration System⁷ function to help recapture energy otherwise lost when brakes are applied. The i-Pedal 3.0 system also now works in reverse and the EV3’s i-Pedal memory function reverts to the last-used i-Pedal setting when the car restarts.

Taking practicality to new heights, the EV3 brings available Vehicle to Load (V2L) functionality,⁸ allowing the vehicle to provide power from its battery to compatible external devices. This can mean everything from powering a laptop, brewing coffee, charging up an e-bike and countless other applications. V2L opens the door to activities and projects that may otherwise require a cumbersome external power source.

Beyond V2L, EV3 also brings available Vehicle to Home (V2H)¹⁸ functionality via a Wallbox bidirectional charging system,¹⁹ which can reduce utility costs by providing power back to the home during peak energy usage times. V2H can also help keep parts of the home powered during outages (requires power recovery unit in addition to bidirectional charger).

Packed with Convenience, Tech and Connectivity Features

The EV3 brings together smart and innovative content to elevate the everyday user experience. This starts with Kia’s available Digital Key 2.0.²⁰ This feature transforms your compatible smartphone or mobile device into a virtual car key, enabling locking/unlocking doors, powering the vehicle on, and sharing vehicle access with others remotely via text.

The EV3 features a standard panoramic display comprised of a 12.3-inch instrument cluster, 5-inch climate display and a 12.3-inch infotainment screen. Together, these elements form the core of Kia’s connected car Navigation Cockpit (ccNC). Setting a new benchmark for in-car content, the Kia-pioneered system which first arrived with the EV9, offers robust connectivity and entertainment features that can be enhanced remotely through over-the-air (OTA) software updates.²¹ Available through the Kia Connect store, Entertainment and Data Services (EDS)¹⁵ is an enhancement to Kia’s existing music streaming and Wi-Fi hotspot services and now includes available video streaming through Netflix and YouTube,¹⁶ in addition to gaming and productivity apps.

The ccNC system also allows drivers to personalize the cockpit with available themed dashboard functions and captivating graphics²² representing some of their favorite sports and entertainment brands, including Disney,²³ Marvel,²⁴ National Geographic,²⁵ Pixar,²⁶ Star Wars,²⁷ FIFA World Cup 2026,²⁸ and the NBA,²⁹ with more on the way. Wireless Apple CarPlay³⁰ and Android Auto³¹ come standard and connect seamlessly to the infotainment system using the smartphone’s Wi-Fi and Bluetooth capabilities.

The EV3 owner can enjoy a more immersive experience with their vehicle by way of Kia’s highly intuitive, voice-recognition-based AI Assistant.³² This system uses machine learning to achieve a higher level of organic interaction between driver and vehicle, which can deepen the human-to-machine interaction over time.

Other available convenience, tech and connectivity features include a 12-inch head-up display (HUD),¹² a premium eight-speaker Harman Kardon³³ audio system, wireless smartphone charging, 360° Surround-View Monitor (SVM),¹³ and MyQ Connected Garage,³⁴ an intuitive garage door management system that brings peace of mind by addressing the question, “Did I close my garage door?”

Advanced Driver Assistance Systems and Driving Convenience

Aside from eight standard airbags,⁹ including rear side airbags, the EV3 offers an impressive suite of ADAS systems¹⁰ that support driving and collision avoidance. Of those, Forward Collision Avoidance (FCA) Assist¹¹ is among the most noteworthy, capable of applying automatic emergency braking in certain circumstances to help avoid a collision or reduce the impact of a crash.

Two applications of FCA are standard FCA Junction Turning (FCA-JT) and available FCA Junction Crossing (FCA-JC).  FCA-JT can help avoid a collision with a detected oncoming vehicle when turning left at an intersection with the turn signal active. FCA-JC monitors the roadway when driving straight across an intersection and is designed to detect vehicles approaching on the left or right side. Both systems are designed to initiate audible and visual alerts followed by automatic emergency braking, in certain circumstances.

Other key driving convenience systems available on the EV3 include Highway Driving Assist 2 (HDA2),³⁵ Reverse Parking Collision Avoidance Assist (PCA-R)³⁶ and Remote Smart Parking Assist (RSPA).³⁷

Kia America – about us

Headquartered in Irvine, California, Kia America continues to top automotive quality surveys. Kia is recognized as one of the TIME World’s Most Sustainable Companies of 2025. Kia serves as the “Official Automotive Partner” of the NBA and WNBA and offers a range of gasoline, hybrid, plug-in hybrid, and electric vehicles sold through a network of nearly 800 dealers in the U.S., including several SUVs proudly assembled in America*. 

For media information, including photography, visit www.kiamedia.com. To receive custom email notifications for press releases the moment they are published, subscribe at www.kiamedia.com/us/en/newsalert 

* Select trims of the all-electric EV6 and EV9 all-electric three-row SUV, Sportage (excludes HEV and PHEV models), Sorento (excludes HEV and PHEV models), and Telluride are assembled in the United States from U.S. and globally sourced parts. 

¹ Charge time based on Kia Corporation testing with 800v DC fast charger and approximately 72 degrees Fahrenheit battery temperature. Actual charge will vary with options, driving conditions, driving habits, vehicle maintenance, charging practice, battery age, weather, temperature and your vehicle’s condition. Battery capacity will decrease with time and use. Frequent use of DC fast charging can negatively impact battery performance and durability, and Kia recommends minimizing use of DC fast charging.

² Electric range shown is not an official EPA estimate and is based on preliminary manufacturer estimates on a vehicle with a full charge. Range will vary and depends on a number of factors, including battery age, vehicle maintenance, charging practice, weather, road/traffic conditions, ambient temperature, driving habits, options, and cargo. Battery capacity will decrease with time and use.

³ To participate in the Plug & Charge program, you must have an active Kia Connect subscription, be signed up for the Kia Charge Pass Program and have a default payment method to cover the costs associated with your vehicle’s charging sessions. Only certain stations offer Plug & Charge services, see https://owners.kia.com/content/owners/en/kia-electrify.html for more details.

⁴ Purchase/lease of a 2026 Kia with Kia Connect includes a complimentary 3-year subscription starting from new vehicle retail sale/lease date as recorded by the dealer. After your complimentary 3-year Kia Connect subscription expires, continued access to the full suite of Kia Connect services available on your Kia will require a paid subscription at the then-current subscription rate, or your use of certain Kia Connect features may immediately terminate. Use of Kia Connect is subject to agreement to the Kia Connect Privacy Policy (available at https://owners.kia.com/us/en/privacy-policy.html) and Terms of Service (available at https://owners.kia.com/us/en/terms-of-service.html). Complimentary Kia Connect subscription is transferable to subsequent owner during the original Kia Connect service term. Only use Kia Connect when safe to do so. Kia Connect may currently be unavailable for some Model Year 2022 and newer vehicles sold or purchased in Massachusetts; please see the Kia Connect Terms of Service for more information. Kia Access App is available from the Apple® App Store® or Google Play Store™. Kia America, Inc. reserves the right to change or discontinue Kia Connect at any time without prior notification or incurring any future obligation. Message and data rates may apply. Cellular and GPS coverage is required to use most features. Kia Connect features may vary by model, model year, and trim level. Features, specifications, and fees are subject to change. For more on details and limitations, visit https://www.kia.com or your authorized Kia dealer. Apple® and App Store® are registered trademarks of Apple Inc.

⁵ No system, no matter how advanced, can compensate for all driver error and/or driving conditions. Always drive safely.

⁶ The i-Pedal system is not a substitute for safe driving.  Do not solely rely on the system to stop the vehicle or avoid collisions. Always drive safely and use caution.

⁷ Regenerative braking is not a substitute for safe driving. Do not solely rely on regenerative braking to stop the vehicle or avoid collisions. Always drive safely and use caution.

⁸ V2L requires the purchase of separately sold additional equipment and may not be compatible with all devices. V2L can be used until a 20 percent battery state of charge. Refer to the vehicle’s Owner’s Manual for warnings and instructions.

⁹ For maximum protection, always wear your seat belt. Please refer to your vehicle’s Owner’s Manual for additional important safety information regarding airbags, including additional cautions and warnings.

¹⁰ When engaged, ADAS systems are not a substitute for safe driving and may not detect all objects around the vehicle. Always drive safely and use caution.

¹¹ When engaged, Forward Collision Avoidance is not a substitute for safe driving and may not detect all objects in front of vehicle. Always drive safely and use caution.

¹² Failure to pay attention to travel conditions and vehicle operation could result in loss of vehicle control. Always drive safely and use caution.

¹³ When engaged, 360° Surround-View Monitor is not a substitute for safe driving, and may not display all objects around vehicle. Always drive safely and use caution.

¹⁴ Comprised of a 12.3-in. instrument display, 5-in. climate display, and 12.3-in. touchscreen infotainment display.

¹⁵ Additional subscriptions may be required for streaming services. Vehicle must be parked for video streaming and gaming features.Entertainment and Data Services is available only in eligible vehicles. A Kia Connect subscription is required. Use of Entertainment and Data Services is subject to agreement to the Kia Connect Privacy Policy (Privacy Policy) and Terms of Service (Terms of Use & Service | Kia). Verizon is the network provider for Entertainment and Data Services, which uses Verizon’s 4G LTE network to transmit data. Data usage applies, and data speed and storage depend on package purchased. Entertainment and Data Services may require vehicle cellular connectivity and availability of vehicle GPS signal; certain services may collect location information. Coverage not available everywhere. See https://www.verizon.com/coverage-map/ for coverage map. Use of Entertainment and Data Services is subject to Verizon Wireless’s Customer Agreement https://www.verizon.com/about/terms-conditions/overview.

¹⁶ YouTube is a trademark of Google LLC. Netflix is a trademark of Netflix Inc.

¹⁷ Use extreme caution when using the seat warmers to avoid burns. Refer to the Owner’s Manual for more safety information.

¹⁸ Vehicle to home (V2H) charging requires purchase of separately sold additional equipment. V2H may not be compatible with all devices and homes. Permits and special permissions may be required and may not be available in certain areas. V2H can be used until the battery’s charge falls to 20 percent. V2H requires an active Kia Connect subscription.

¹⁹ Wallbox Power Recovery Unit is required for Backup Power functionality; Quasar 2 charger alone cannot power home in the event of electrical grid blackout. Quasar 2 and Power Recovery Unit may not be compatible with all devices and homes. Backup Power feature is projected to provide up to 2.5 days of power in areas of a home, based on an average 25 kWh daily usage and 81.4 kWh battery with 100% charge at start, when the home is properly equipped. Results, including time it takes to charge, may vary depending on your actual energy consumption, vehicle usage and maintenance, charging practice, battery age, weather, temperature, size of home or area, battery’s state of charge, and other factors. Backup Power feature can be used until a 20% battery state of charge. Quasar 2 and Power Recovery Unit must be in a residential garage or carport with shade and ventilation.

²⁰Kia Digital Key 2.0 requires an eligible Kia Connect subscription and a compatible smart device with an active data plan. Normal cellular service rates may apply when using a smart device.

²¹ Over-the-Air features and updates may require an additional cost and may vary by model, model year, and trim level. Features, specifications, and fees are subject to change. Kia Connect subscription is required and Kia Connect terms and conditions apply.

²² Display Themes are only available on models that have the latest ccNC (Connected Car Navigation Cockpit) based infotainment system. An active Kia Connect subscription is required to utilize Display Themes. Without an active Kia Connect subscription, Display Themes will not be operational. Once purchased, Display Themes are limited to use on the specific vehicle tied to purchase and cannot be transferred to other vehicles.

²³ ©Disney

²⁴ © Marvel

²⁵ © National Geographic Partners, LLC.

²⁶ © Disney/Pixar

²⁷ © & TM Lucasfilm Ltd.

²⁸ FIFA World Cup 2026 ™

²⁹ © 2026 NBA Properties, Inc. All rights reserved.

³⁰ Apple CarPlay®: Apple® and Apple CarPlay® are trademarks of Apple, Inc., registered in the U.S. and other countries. Apple CarPlay® runs on your smartphone cellular data service. Normal data rates will apply.

³¹ Android Auto™: Vehicle user interface is a product of Google, and its terms and privacy statements apply. Requires the Android Auto app on Google Play and an Android-compatible smartphone running Android™ 5.0 Lollipop or higher. Data plan rates apply. Android Auto is a trademark of Google LLC.

³² Kia Connect subscription required. Use of the feature is subject to the Kia Connect Terms of Service and Privacy Policy. May be currently unavailable for vehicles purchased or sold in Massachusetts that are not eligible for Kia Connect. Kia does not make any warranties about the accuracy of the information provided. Distracted driving can result in a loss of vehicle control. When operating a vehicle, never use a vehicle system that takes your focus away from safe vehicle operation.

³³ Harman/Kardon is a registered trademark of Harman International Industries, Inc.

³⁴ Kia myQ Connected Garage is available only on vehicles with a ccNC head unit. Kia Connect and myQ accounts are required to activate your myQ-enabled garage door opener. This feature depends on various other factors in the vehicle such as LTE network coverage to transmit data. Coverage not available everywhere. Certain services may collect location information and data usage applies. Kia Connect terms and conditions apply. Kia myQ Connected Garage is subject to a functioning link between Kia Connect and myQ accounts, as well as myQ systems availability. Speed of the network communication is dependent on the systems and LTE network coverage.

³⁵ When engaged, Highway Driving Assist is not a substitute for safe driving, may not detect all objects surrounding the vehicle,and only functions on certain federal highways. Always drive safely and use caution.

³⁶ When engaged, Parking Collision-Avoidance Assist-Reverse is not a substitute for safe driving and may not detect all objectsbehind the vehicle. Always drive safely and use caution.

³⁷ Remote Smart Parking Assist requires driver engagement and may not detect all objects around the vehicle. Please see the Owner’s Manual for limitations, warnings, and instructions.

 

 

 

 

 

View original content:https://www.prnewswire.com/news-releases/the-all-new-2027-kia-ev3-debuts-at-new-york-international-auto-show-302730776.html

SOURCE Kia America